MAAT PHARMA overview

Regulatory News: This replaces the announcement made at 18:00 CET on 9 December 2024 due to the following corrections: Updated subheadline. MaaT Pharma Presented Positive Updated Data on MaaT013 in the Early Access Program at ASH 2024 Annual Meeting MaaT Pharma to host a KOL webinar on December 17 th , 2024, to discuss data and the unmet medical need in acute Graft-versus-Host Disease (aGvHD) - Register here . Sustained High Response Rates at Day 28: Gastrointestinal Overall Response Rate...

Regulatory News: MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies TM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, announced that Prof. Malard, MD, hematology professor at Saint-Antoine Hospital and Sorbonne University, today detailed updated data for 154 patients with acute Graft-versus-Host Disease (aGvHD) treated with MaaT013 in Early Access...

Regulatory News: MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies TM (MET) dedicated to enhancing survival of patients with cancer, announced the first treatment in the United States of a patient with acute Graft-versus-Host Disease (aGvHD) under the US Food and Drug Administration (FDA) Single Patient Expanded Access. Expanded access, sometimes called “compassionate use,” is a...

Regulatory News: MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies TM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, announced that the exploratory single-arm, open-label Phase 1b clinical trial named IASO ( NCT05889572 ) evaluating MaaT033 in ALS has met its primary endpoint assessing the safety and tolerability of MaaT033 with multiple doses. The...

Regulatory News: MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies TM (MET) dedicated to improving survival outcomes for patients with cancer, today published the number of shares comprising the share capital and the total number of voting rights (Article L. 233-8 of the French Commercial Code (Code de commerce) and Article 223-16 of the General Regulations of French Autorité des Marchés...

Regulatory News: MaaT Pharma (EURONEXT: MAAT – the “Company”), a French clinical-stage biotech and a pioneer in the development of Microbiome Ecosystem Therapies TM (MET) dedicated to improving survival outcomes for patients with cancer, today provided a business update and reported its cash position as of June 30, 2023 and its revenues for the second quarter of 2023. "As a leading microbiome company in oncology, we are proud of the progress made in the second quarter of 2023. We are...

Regulatory News: MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies TM (MET) dedicated to improving survival outcomes for patients with cancer , today announced that eClinicalMedicine has published clinical data on MaaT013 as a treatment for acute Graft-versus-Host Disease (aGvHD). The data includes results from 24 patients in a Phase 2 clinical trial and 52 patients enrolled in the Early...